Provided by Tiger Fintech (Singapore) Pte. Ltd.

Werewolf Therapeutics, Inc.

1.24
+0.07005.98%
Pre-market: 1.300.0600+4.84%08:00 EST
Volume:263.83K
Turnover:329.34K
Market Cap:55.26M
PE:-0.81
High:1.29
Open:1.17
Low:1.17
Close:1.17
Loading ...

Werewolf Therapeutics to Present at the 2025 Leerink Partners Global Biopharma Conference

GlobeNewswire
·
04 Mar

Pacira (PCRX) Tops Q4 Earnings Estimates

Zacks
·
28 Feb

Werewolf Therapeutics Appoints Anil Singhal to Board

TIPRANKS
·
24 Feb

Werewolf Therapeutics appoints Anil Singhal to board of directors

TIPRANKS
·
24 Feb

Werewolf Therapeutics Appoints Anil Singhal, Ph.d., to Its Board of Directors

THOMSON REUTERS
·
24 Feb

Press Release: Werewolf Therapeutics Appoints Anil Singhal, Ph.D., to its Board of Directors

Dow Jones
·
24 Feb

Oramed Pharmaceuticals And 2 Other US Penny Stocks To Watch

Simply Wall St.
·
12 Feb

Werewolf Therapeutics price target lowered to $4 from $12 at JMP Securities

TIPRANKS
·
14 Jan

Buy Rating Affirmed for Werewolf Therapeutics Amid Strategic Advancements and Strong Financial Position

TIPRANKS
·
14 Jan

Werewolf Therapeutics provides business update, highlights 2025 outlook

TIPRANKS
·
13 Jan

Werewolf Therapeutics Inc - Data From Wtx-124 Monotherapy Trial Expected in H1 2025

THOMSON REUTERS
·
13 Jan

Werewolf Therapeutics Provides Business Update and Highlights 2025 Strategic Outlook

THOMSON REUTERS
·
13 Jan

Werewolf Therapeutics Inc - Data From Wtx-124 Combo Trial Expected in Q4 2025

THOMSON REUTERS
·
13 Jan

Werewolf Therapeutics Inc - Cash Runway Expected Through Q2 2026

THOMSON REUTERS
·
13 Jan

Werewolf Therapeutics Provides Business Update and Highlights 2025 Strategic Outlook

GlobeNewswire
·
13 Jan

Werewolf Therapeutics to Participate in the 7th Annual Evercore ISI HealthCONx Healthcare Conference

GlobeNewswire
·
20 Nov 2024